Yumanity snags a CMO as Shire keeps bleeding execs

Hand holding a light bulb with a brain inside it
A psychiatrist by training, Brigitte Robertson, M.D., got her industry start at GlaxoSmithKline before moving onto Sunovion Pharma and then Shire. (baramee2554/iStock/Getty Images Plus)

As Takeda’s Shire buyout rumbles on, yet another R&D exec has found a new home. Brigitte Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer. 

Robertson is just the latest in a stream of executives to exit the rare disease specialist as it gets subsumed by Takeda. 

This year, Shire’s former R&D chief, Andy Busch, Ph.D., and Howard Mayer, M.D., its ex-CMO, vice president and neuroscience R&D head both headed to greener pastures—Busch to Cyclerion as its chief innovation officer and Mayer to Ipsen as its new R&D chief. Another alum, David Altarac, M.D., landed at the AstraZeneca spinout Entasis as its CMO having been head of global regulatory affairs, global drug safety and R&D quality and compliance at Shire. 

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: Pfizer spinout Cerevel hires Coles as CEO 

Robertson spent more than eight years at Shire, first as a senior medical director and global development strategy lead and then as head of the neuroscience therapeutic area and vice president of global clinical development. In between, she had a stint at ADHD-focused Neurovance as its CMO. 

RELATED: Hemophilia rivalry eats away at post-Shire Takeda—and its Natpara recall bites, too

A psychiatrist by training, Robertson got her industry start at GlaxoSmithKline before moving on to Sunovion Pharma and then Shire. 

“As Yumanity Therapeutics has now reached the clinical stage, Dr. Robertson’s experience driving the global development of multiple industry-leading neurology clinical programs will help ensure expert efficiency in our pursuit of next-generation therapeutic solutions to combat challenging neurodegenerative diseases,” Yumanity CEO Richard Peters, M.D., Ph.D., said in a statement. Peters himself is a recent addition to Yumanity, having succeeded Tony Coles, who took the helm of Pfizer spinout Cerevel Therapeutics in July.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.